These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 33541326)

  • 1. Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study.
    Nam B; Koo BS; Lee TH; Shin JH; Kim JJ; Lee S; Joo KB; Kim TH
    BMC Musculoskelet Disord; 2021 Feb; 22(1):140. PubMed ID: 33541326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy.
    Vastesaeger N; Cruyssen BV; Mulero J; Gratacós Masmitjá J; Zarco P; Almodovar R; Font P; Juanola X; Collantes-Estevez E;
    Reumatol Clin; 2014; 10(4):204-9. PubMed ID: 24598027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validity and reliability of the Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in patients with axial spondyloarthritis (axSpA) in Singapore.
    Kwan YH; Tan JJ; Phang JK; Fong W; Lim KK; Koh HL; Lui NL; Tan CS; Østbye T; Thumboo J; Leung YY
    Int J Rheum Dis; 2019 Dec; 22(12):2206-2212. PubMed ID: 31721427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry.
    Tužil J; Mlčoch T; Jirčíková J; Závada J; Nekvindová L; Svoboda M; Uher M; Křístková Z; Vencovský J; Pavelka K; Doležal T
    Expert Opin Biol Ther; 2020 Feb; 20(2):183-192. PubMed ID: 31736377
    [No Abstract]   [Full Text] [Related]  

  • 5. Construct validity and responsiveness of the simplified version of Ankylosing Spondylitis Disease Activity Score (SASDAS) for the evaluation of disease activity in axial spondyloarthritis.
    Salaffi F; Ciapetti A; Carotti M; Gasparini S; Citera G; Gutierrez M
    Health Qual Life Outcomes; 2014 Aug; 12():129. PubMed ID: 25146299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.
    Arends S; Brouwer E; van der Veer E; Groen H; Leijsma MK; Houtman PM; Th A Jansen TL; Kallenberg CG; Spoorenberg A
    Arthritis Res Ther; 2011 Jun; 13(3):R94. PubMed ID: 21689401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construct validity of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) treatment target cut-offs in a BASDAI treat-to-target axial spondyloarthritis cohort: a cross-sectional study.
    Michielsens C; Bolhuis TE; van Gaalen FA; van den Hoogen F; Verhoef LM; den Broeder N; den Broeder AA
    Scand J Rheumatol; 2024 May; 53(3):180-187. PubMed ID: 37339375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discriminant validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis: a cohort study.
    Kilic E; Kilic G; Akgul O; Ozgocmen S
    Rheumatol Int; 2015 Jun; 35(6):981-9. PubMed ID: 25366469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Equivalent cut-off values of Bath Ankylosing Spondylitis Disease Activity Index corresponding to Ankylosing Spondylitis Disease Activity Score cut-off values.
    Cui R; Du Y; Tian N; Jiang HL; Tao YL; Dai SM
    Clin Exp Rheumatol; 2023 May; 41(5):1163-1169. PubMed ID: 36226617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria.
    Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Kaufmann C; Rødevand E; Mikkelsen K; Kalstad S; Kvien TK
    Rheumatology (Oxford); 2012 Aug; 51(8):1479-83. PubMed ID: 22499062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.
    van der Heijde D; Lie E; Kvien TK; Sieper J; Van den Bosch F; Listing J; Braun J; Landewé R;
    Ann Rheum Dis; 2009 Dec; 68(12):1811-8. PubMed ID: 19060001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The value of ankylosing spondylitis disease activity score in evaluating disease activity of ankylosing spondylitis].
    DU XN; Li Y; Zhang SL; Zhu J; Huang F
    Zhonghua Nei Ke Za Zhi; 2012 Mar; 51(3):206-9. PubMed ID: 22781894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The predictability of ASDAS on drug survival in patients with ankylosing spondylitis on biologic therapy: data from the KOBIO registry.
    Kim J; Kim MJ; Oh GY; Lee SK; Kim T; Shin K
    Ther Adv Musculoskelet Dis; 2023; 15():1759720X231201714. PubMed ID: 37822329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease activity assessment in ankylosing spondylitis in a Chinese cohort: BASDAI or ASDAS?
    Au YL; Wong WS; Mok MY; Chung HY; Chan E; Lau CS
    Clin Rheumatol; 2014 Aug; 33(8):1127-34. PubMed ID: 24981160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
    Pedersen SJ; Sørensen IJ; Hermann KG; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Johansen JS; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Hansen A; Ostergaard M
    Ann Rheum Dis; 2010 Jun; 69(6):1065-71. PubMed ID: 19740906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Discriminative Values of the Bath Ankylosing Spondylitis Disease Activity Index, Ankylosing Spondylitis Disease Activity Score, C-Reactive Protein, and Erythrocyte Sedimentation Rate in Spondyloarthritis-Related Axial Arthritis.
    Tsang HHL; Chung HY
    J Clin Rheumatol; 2017 Aug; 23(5):267-272. PubMed ID: 28661926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet to albumin ratio is an independent indicator for disease activity in ankylosing spondylitis.
    Cui R; Wang YL; Tao YL; Tong Q; Chen Z; Dai SM
    Clin Rheumatol; 2023 Feb; 42(2):407-413. PubMed ID: 36414863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Ankylosing Spondylitis Disease Activity Score is a highly discriminatory measure of disease activity and efficacy following tumour necrosis factor-α inhibitor therapies in ankylosing spondylitis and undifferentiated spondyloarthropathies in China.
    Xu M; Lin Z; Deng X; Li L; Wei Y; Liao Z; Li Q; Wei Q; Hu Z; Zhang Y; Lin Q; Huang J; Li T; Pan Y; Wu Y; Jin O; Yu B; Gu J
    Rheumatology (Oxford); 2011 Aug; 50(8):1466-72. PubMed ID: 21441550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brief Report: Clinical Course Over Two Years in Patients With Early Nonradiographic Axial Spondyloarthritis and Patients With Ankylosing Spondylitis Not Treated With Tumor Necrosis Factor Blockers: Results From the German Spondyloarthritis Inception Cohort.
    Poddubnyy D; Haibel H; Braun J; Rudwaleit M; Sieper J
    Arthritis Rheumatol; 2015 Sep; 67(9):2369-75. PubMed ID: 26017497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.
    Lopalco G; Venerito V; Cantarini L; Emmi G; Salaffi F; Di Carlo M; Tafuri S; Gentileschi S; Di Scala G; Nivuori M; Cacciapaglia F; Galeazzi M; Lapadula G; Iannone F
    Clin Exp Rheumatol; 2019; 37(5):762-767. PubMed ID: 31025925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.